Hudson Bay Capital Management LP Boosts Stake in Dynavax Technologies Corporation $DVAX

Hudson Bay Capital Management LP lifted its stake in Dynavax Technologies Corporation (NASDAQ:DVAX) by 46.4% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 541,600 shares of the biopharmaceutical company’s stock after purchasing an additional 171,700 shares during the quarter. Hudson Bay Capital Management LP’s holdings in Dynavax Technologies were worth $5,373,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of DVAX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Dynavax Technologies by 1.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 86,421 shares of the biopharmaceutical company’s stock worth $1,126,000 after buying an additional 1,625 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its position in shares of Dynavax Technologies by 5,485.7% during the first quarter. Caitong International Asset Management Co. Ltd now owns 2,346 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 2,304 shares in the last quarter. E Fund Management Co. Ltd. raised its stake in Dynavax Technologies by 17.9% during the 2nd quarter. E Fund Management Co. Ltd. now owns 18,113 shares of the biopharmaceutical company’s stock valued at $180,000 after purchasing an additional 2,752 shares during the period. Charles Schwab Investment Management Inc. raised its stake in Dynavax Technologies by 0.3% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,157,993 shares of the biopharmaceutical company’s stock valued at $15,019,000 after purchasing an additional 2,913 shares during the period. Finally, Nordea Investment Management AB lifted its holdings in Dynavax Technologies by 0.4% in the 2nd quarter. Nordea Investment Management AB now owns 782,248 shares of the biopharmaceutical company’s stock worth $7,830,000 after purchasing an additional 3,171 shares in the last quarter. Hedge funds and other institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Trading Up 0.5%

DVAX stock opened at $10.85 on Tuesday. The firm has a market cap of $1.27 billion, a PE ratio of -29.32 and a beta of 0.88. The firm has a fifty day moving average price of $10.66 and a 200 day moving average price of $10.43. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.94 and a current ratio of 7.62. Dynavax Technologies Corporation has a fifty-two week low of $9.20 and a fifty-two week high of $14.63.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported $0.21 EPS for the quarter, beating the consensus estimate of $0.14 by $0.07. Dynavax Technologies had a negative net margin of 13.13% and a positive return on equity of 7.18%. The business had revenue of $94.88 million during the quarter, compared to analyst estimates of $94.00 million. Sell-side analysts anticipate that Dynavax Technologies Corporation will post 0.32 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $32.00 price objective on shares of Dynavax Technologies in a report on Friday, August 22nd. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Dynavax Technologies in a research note on Wednesday, October 8th. Three investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $24.33.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.